These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 7856324

  • 1. [Effect of clozapine on biogenic amines within the scope of drug treatment of schizophrenic psychoses in adolescence].
    Schulz E, Remschmidt H, Fleischhaker C.
    Z Kinder Jugendpsychiatr; 1994 Dec; 22(4):285-98. PubMed ID: 7856324
    [Abstract] [Full Text] [Related]

  • 2. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
    Fleischhaker C, Schulz E, Remschmidt H.
    Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
    [Abstract] [Full Text] [Related]

  • 3. Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia.
    Fleischhaker C, Schulz E, Remschmidt H.
    J Psychiatr Res; 1998 Dec; 32(5):325-33. PubMed ID: 9789212
    [Abstract] [Full Text] [Related]

  • 4. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia.
    Schulz E, Fleischhaker C, Remschmidt HE.
    J Child Adolesc Psychopharmacol; 1996 Dec; 6(2):119-31. PubMed ID: 9231304
    [Abstract] [Full Text] [Related]

  • 5. Blood biogenic amines during clozapine treatment of early-onset schizophrenia.
    Schulz E, Fleischhaker C, Clement HW, Remschmidt H.
    J Neural Transm (Vienna); 1997 Dec; 104(10):1077-89. PubMed ID: 9503259
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S, Iwamoto N, Arai H.
    Biol Psychiatry; 1997 Apr 15; 41(8):857-64. PubMed ID: 9099412
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms.
    Ma N, Tan LW, Wang Q, Li ZX, Li LJ.
    Psychiatry Res; 2007 Feb 28; 150(1):61-9. PubMed ID: 17291595
    [Abstract] [Full Text] [Related]

  • 13. [Clozapine and treatment of negative symptoms].
    Lançon C, Farisse J, Llorca PM.
    Encephale; 1997 Sep 28; 23 Spec No 4():7-11. PubMed ID: 9417403
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M, Kuwilsky A, Krumm B, Dressing H.
    J Psychopharmacol; 2009 May 28; 23(3):305-14. PubMed ID: 18562423
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Clozapine and refractory schizophrenia. Long-term prospective study of 20 patients].
    Jalenques I, Coudert AJ.
    Encephale; 1994 May 28; 20(6):767-75. PubMed ID: 7875111
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.